Evidence map›Paper›PMID 42289639›Full record

ArticleAnnals of surgical oncology2026

Survival Comparison of Proximal and Total Gastrectomy after Neoadjuvant Therapy in Siewert Type II/III Gastric Adenocarcinoma: A Real-World Multicenter Cohort Study.

Ze-Lin Wen, Hu Ren, Peng-Hui Niu, Xiao-Jie Zhang, He Fei, Dong-Shuai Jing, Ze-Feng Li, Diliyaer Adili, Hong-Xu Nie, Lei Zhou and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ze-Lin Wen *National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hu Ren *National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Peng-Hui Niu *National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xiao-Jie Zhang *China-Japan Friendship Hospital, Beijing, China.
He Fei *National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Dong-Shuai Jing *The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
Ze-Feng LiNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Diliyaer AdiliNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hong-Xu NieNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Lei ZhouChina-Japan Friendship Hospital, Beijing, China. zhoulei1971@hotmail.com.
De-Chun LiuThe First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China. liudechun2008@126.com.
Dong-Bing ZhaoNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. dbzhao@cicams.ac.cn.ORCID http://orcid.org/0000-0002-6770-2694

Funding

Beijing Hope Run Special Fund of Cancer Foundation of China LC2022L03
6 · The paper itself

Abstract

backgroundThe optimal extent of gastrectomy after neoadjuvant therapy for Siewert II/III gastric adenocarcinoma remains unclear. The objective of this study was to compare survival after proximal versus total gastrectomy and to assess the prognostic impact of distal nodal station metastasis (nos. 4d, 5, 6, and 12a). PATIENTS AND

methodsWe retrospectively analyzed 824 patients with Siewert II/III gastric adenocarcinoma who received neoadjuvant chemotherapy and underwent proximal gastrectomy (PG) or total gastrectomy (TG) at three Chinese centers (2010-2025). Following propensity score matching, survival analysis was performed on a balanced cohort of 518 patients. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier analysis and Cox regression.

resultsPG and TG achieved comparable OS and PFS (OS P = 0.54; PFS P = 0.86), with consistent findings across Siewert subtype, pathologic T stage, and TNM stage strata. No significant differences were observed in N0 or N

conclusionsPG provides survival comparable to TG after neoadjuvant therapy. The distal key station exhibits a significantly higher metastatic incidence in patients with stage III gastric cancer.

Indexed as

Neoadjuvant therapyProximal gastrectomySurvivalTotal gastrectomy

Identifiers

PMID42289639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.